Scribe Therapeutics (SCTX) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Scribe Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $71.3M and 0 sold $0 of SCTX stock on the open market, including a cluster buy that began Jul 23, 2026.
Get emailed when insiders cluster-buy stocks like SCTX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SCTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $71.3M | 9 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 6 Scribe Therapeutics, Inc. insiders reported open-market purchases totaling $71.3M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Jul 23, 2026, when 6 insiders bought a combined $71.3M.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 29SEC | Orbimed Advisors LlcDirector | Buy | 1,000,0001,348,825 held (+287%) | $15.00 | $15.0M | +41.1% | — |
| Jul 29SEC | Carl L GordonDirector | Buy | 1,000,0001,348,825 held (+287%) | $15.00 | $15.0M | +41.1% | — |
| Jul 29SEC | Ah Equity Partners Bio Ii, L.L.C.10% Owner | Buy | 333,3332,385,075 held (+16%) | $15.00 | $5.0M | +41.1% | — |
| Jul 28SEC | Avoro Ventures LlcSee Remarks | Buy | 2,333,3333,030,983 held (+334%) | $15.00 | $35.0M | +41.1% | — |
| Jul 28SEC | Avoro Ventures LlcSee Remarks | Buy | 50,0003,080,983 held (+2%) | $22.31 | $1.1M | -5.1% | — |
| Jul 28SEC | Avoro Ventures LlcSee Remarks | Buy | 7,9053,088,888 held (+0%) | $18.25 | $144K | +16.0% | — |
| Jul 27SEC | Svetlana LucasChief Business Officer | Buy | 3,000new position | $15.00 | $45K | +41.1% | — |
| Jul 27SEC | David ParrotCFO | Buy | 1,333new position | $15.00 | $20K | +41.1% | — |
| Jul 27SEC | David ParrotCFO | Buy | 1,333new position | $15.00 | $20K | +41.1% | — |
Insiders at Scribe Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Avoro Ventures LlcSee Remarks | $36.3M | — | Jul 28, 2026 | — |
| Orbimed Advisors LlcDirector | $15.0M | — | Jul 29, 2026 | — |
| Carl L GordonDirector | $15.0M | — | Jul 29, 2026 | — |
| Ah Equity Partners Bio Ii, L.L.C.10% Owner | $5.0M | — | Jul 29, 2026 | — |
| Svetlana LucasChief Business Officer | $45K | — | Jul 27, 2026 | — |
| David ParrotCFO | $40K | — | Jul 27, 2026 | — |
SCTX stock: common questions
Are Scribe Therapeutics, Inc. insiders buying SCTX stock?
In the past 12 months, 6 insiders reported open-market purchases of SCTX worth $71.3M. The latest was Director Orbimed Advisors Llc bought $15.0M of SCTX at $15.00 — first open-market purchase in our records; raises the stake by 287%.
Are Scribe Therapeutics, Inc. insiders selling SCTX stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SCTX's 52-week range?
Over the past year SCTX has traded between $16.21 and $37.25. It last closed at $21.17 on Oct 9, 2026.